Acute Lymphoblastic Leukemia: Pharmacologic Management
Acute lymphoblastic leukemia (ALL) is the most prevalent pediatric leukemia and makes up one-quarter of cancer cases among adolescents and children younger than 15 years.
Acute lymphoblastic leukemia (ALL) is the most prevalent pediatric leukemia and makes up one-quarter of cancer cases among adolescents and children younger than 15 years.
Acute myeloid leukemia (AML) is the most prevalent adult acute leukemia. According to the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, as many as 20,380 cases of AML will be diagnosed in 2023.
Adult T-cell lymphoma is a rare type of non-Hodgkin lymphoma (NHL) that affects T lymphocytes and natural killer (NK) cells. They are a group of heterogeneous malignancies that account for 12% of all NHL cases
Anal cancer, of which fewer than 10,000 patients are diagnosed annually in the United States, is an uncommon type of cancer occurring in the tissue of the anus.
Biliary tract cancers are a rare but deadly form of cancer that account for 2% to 3% of all malignancies in the United States.1 Biliary tract cancer typically presents between the ages of 60 and 70 years.
The best bladder cancer treatment option may include more than one type or combination of different treatments (chemotherapy, radiation, and surgery)
Bladder cancer is the sixth most prevalent cancer in the United States. As of 2023, 82,290 new diagnoses of bladder cancer (62,420 in men and 19,870 in women) were documented, as well as 16,710 deaths.
Primary bone cancers are rare cancers that arise from primitive mesenchymal cells from which all connective tissues are derived. Bone cancer accounts for 0.2% of all cancers.
Glioblastoma multiforme (GBM) is the most malignant and frequently diagnosed primary brain tumor, accounting for more than 60% of all brain cancer diagnoses in adults.
The National Cancer Institute estimates that there will be 297,790 new cases of invasive breast cancer and 55,720 new cases of ductal carcinoma in situ (DCIS) diagnosed in 2023.